BUSINESS

• Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
  January 10, 2023

• Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
  January 10, 2023

• Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
  January 10, 2023

• Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
  January 10, 2023

• Kaken Earns Japan Rights to CAH Med, Poised to Boost Rare Disease Biz
  January 10, 2023

• Nippon Shinyaku Launches Open Innovation-Driven Drug Discovery Hub in US
  January 10, 2023

• Fujifilm US Subsidiary Licenses iPSC Platform to Novo
  January 10, 2023

• US Federal Circuit Nixes Lexiscan Patent Infringement, Astellas to File Appeal
  January 6, 2023

• Dayvigo Tops HP Ranking, Twymeeg Most Promoted in GP Market 5 Months Running in November: Intage
  January 6, 2023

• Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
  January 6, 2023

• Xocova Filed for Conditional Approval in South Korea
  January 6, 2023

• Enhertu’s Application for NSCLC Use Accepted in Europe: Daiichi Sankyo
  January 6, 2023

• Moderna Snags Tokyo Upstart in Its 1st M&A Deal, Staff to Join Japan Unit
  January 6, 2023

• Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
  January 5, 2023

• Steve Sugino Becomes New CEO of BMS Japan
  January 5, 2023

• Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
  January 5, 2023

• Sun Pharma Japan Gearing Up Sales of Flagship Dermatology Med Ilumya: President
  December 28, 2022

• RaQualia, Veritas Seal mRNA Drug Discovery Collaboration
  December 28, 2022

• PeptiDream, Lilly Ink Collab with Up to US$1.2 Billion in Milestones
  December 27, 2022

• Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
  December 27, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 162
• 163
• 164
• 165
• 166
• 167
• 168
• 169
• 170
• …
• Next ›
• 最終 »